Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will present and host investor meetings at multiple January investor conferences, including the Sachs Associates 9th Annual Neuroscience Innovation Forum and Biotech Showcase 2026, both held in San Francisco. President and Chief Executive Officer Seth Lederman, M.D., is scheduled to deliver a company presentation and participate in a panel discussion focused on neuropsychiatric drug development at the Sachs Associates forum, and to present at Biotech Showcase 2026, with a replay of the presentation expected to be made available on the company's website following the event.
The company's participation in these high-profile forums underscores its position as a fully-integrated biotechnology firm with both marketed products and a substantial pipeline. Tonix markets FDA-approved TONMYA(TM), a first-in-class, non-opioid analgesic medicine for the treatment of fibromyalgia, a chronic pain condition affecting millions of adults. TONMYA represents the first new prescription medicine approved by the FDA for fibromyalgia in more than 15 years. Additionally, Tonix markets two treatments for acute migraine in adults: Zembrace(R) SymTouch(R) (sumatriptan injection) and Tosymra(R) (sumatriptan nasal spray).
Tonix's development portfolio is notably diverse, focusing on central nervous system (CNS) disorders, immunology, immuno-oncology, rare disease and infectious disease. The CNS pipeline includes TNX-102 SL, which is being developed to treat acute stress reaction and acute stress disorder under an Investigator-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). TNX-102 SL is also in development for major depressive disorder.
In immunology, Tonix is advancing TNX-1500, a Phase 2-ready Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. The rare disease portfolio includes TNX-2900, intranasal oxytocin potentiated with magnesium, in development for Prader-Willi syndrome and expected to start a potential pivotal Phase 2 study in 2026.
The infectious disease portfolio represents another significant area of focus, featuring TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4800, a Phase 2-ready long-acting humanized monoclonal antibody for the seasonal prevention of Lyme disease. Additionally, TNX-4200, for which Tonix has a contract with the U.S. DoD's Defense Threat Reduction Agency (DTRA) for up to $34 million over five years, is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of high lethality infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the-art infectious disease research facility in Frederick, Md.
It is important to note that Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and they have not been approved for any indication. The latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP. The full press release for this announcement can be viewed at https://ibn.fm/l7Ohq.
For investors and industry observers, these conference presentations provide a critical opportunity to assess Tonix's strategic direction, pipeline progress, and commercial execution. The breadth of the pipeline, spanning from marketed products in chronic pain and migraine to advanced development candidates in areas with significant unmet medical need like autoimmune diseases, rare disorders, and infectious threats, highlights the company's multifaceted approach to value creation. The involvement in DoD-funded projects further underscores the potential broader public health and national security implications of its research. These engagements are typical for biotechnology companies seeking to maintain visibility, attract potential partners, and secure the capital necessary to advance complex, long-term research and development programs.
